# HoxA9 Homeobox: Homeodomain DNA-Binding Architecture, Body Axis Patterning, and Leukemic Transformation


## Key Takeaways

- HOXA9 is a sequence-specific DNA-binding transcription factor crucial for anterior-posterior body axis patterning during embryogenesis and for maintaining self-renewal versus differentiation balance in adult hematopoiesis. Its dysregulation is implicated in acute myeloid leukemia (AML) and various solid tumors.
- The HOXA9 gene is located on chromosome 7p15.2 and is part of the HOXA cluster. Aberrant chromosomal translocations, such as t(7;11)(p15;p15) creating the NUP98-HOXA9 fusion protein, are pathogenic drivers in a subset of AML and myelodysplastic syndromes.
- HOXA9's promoter is a CpG island regulated epigenetically; hypermethylation leads to transcriptional silencing in many solid tumors, while aberrant overexpression in AML is often driven by MLL rearrangements or NPM1 mutations, sustained by active chromatin states.
- The HOXA9 protein comprises an N-terminal regulatory domain and a C-terminal homeodomain (helix-turn-helix motif) responsible for DNA binding. Its specificity and affinity are significantly enhanced by cooperative binding with cofactors like PBX1/PBX3 and MEIS1.
- Therapeutic strategies targeting HOXA9 dysregulation include inhibitors of the Menin-MLL interaction (e.g., DSP-5336), epigenetic modulators (DOT1L, LSD1 inhibitors), and direct HOXA9 inhibitors that block DNA binding or overcome differentiation arrest in AML.
- HOXA9 exhibits context-dependent roles in solid tumors, acting as an oncogene in ovarian and colorectal cancers, but as a tumor suppressor in cutaneous squamous cell carcinoma and breast cancer, often through epigenetic silencing or modulation of key genes like BRCA1.

---

## Executive Summary & Key Metadata

The Homeobox A9 gene (HOXA9) encodes a sequence-specific DNA-binding transcription factor that orchestrates anterior-posterior body patterning during embryogenesis and governs the delicate balance between self-renewal and differentiation in adult hematopoiesis. Its dysregulation—through chromosomal translocation, epigenetic silencing, or aberrant overexpression—represents a central node in the pathogenesis of acute myeloid leukemia (AML) and a growing list of solid tumors. This reference manual provides a definitive, biophysically grounded analysis of HOXA9, from its genomic architecture and three-dimensional [protein structure](/knowledge/bioinformatics/protein-structure-biophysical-levels-folding) to its complex signaling networks, pathogenic mutations, and emerging therapeutic vulnerabilities.

| **Attribute** | **Detail** |
| :--- | :--- |
| **HGNC Symbol** | HOXA9 |
| **UniProt Accession** | P31269 |
| **Representative PDB ID** | 1K28 |
| **Chromosomal Locus** | 7p15.2 (GRCh38: chr7:27,084,169-27,087,563) |
| **Primary Molecular Function** | Sequence-specific DNA-binding transcription factor (homeodomain) regulating developmental and hematopoietic gene expression programs [1, 2] |
| **Disease & Pathology Associations** | Acute Myeloid Leukemia (AML), Mixed Lineage Leukemia (MLL-r), Myelodysplastic Syndromes, Ovarian Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Glioblastoma [3, 4, 5, 6, 7, 8, 9, 10, 11] |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Location and Gene Structure

HOXA9 resides within the HOXA cluster, one of four paralogous clusters (HOXA, HOXB, HOXC, HOXD) that arose from ancestral duplication events during early vertebrate evolution. The human HOXA cluster is located on the short arm of chromosome 7 at band p15.2. The HOXA9 gene itself spans approximately 3.4 kilobases of genomic DNA and consists of two exons separated by a single intron of roughly 1.5 kilobases [12]. The canonical transcript (NM_152739.4) encodes a 272-amino acid protein.

The genomic coordinates for HOXA9 are critical for clinical cytogenetics, particularly for identifying the t(7;11)(p15;p15) translocation, which fuses the nucleoporin gene *NUP98* to *HOXA9* [13, 14]. This translocation is a recurrent, albeit rare, event in AML and myelodysplastic syndromes (MDS), occurring in approximately 1-2% of adult AML cases [3]. The breakpoints on chromosome 7 are heterogeneous, but all result in an in-frame fusion that places the N-terminal FG-repeat domain of NUP98 upstream of the HOXA9 homeodomain [15].

### 1.2 Promoter Architecture and Regulatory Elements

The promoter region of HOXA9 is a complex regulatory hub, devoid of a canonical TATA box but rich in CpG dinucleotides, forming a large CpG island. This CpG island is a primary target for epigenetic regulation. In normal cells, the promoter is maintained in a hypomethylated state, permitting active transcription. However, in numerous solid tumors, including hepatocellular carcinoma, oral squamous cell carcinoma, and non-small cell lung cancer, the HOXA9 promoter becomes aberrantly hypermethylated, leading to transcriptional silencing [5, 16, 17]. This methylation-mediated silencing is a frequent event and has been investigated as a circulating tumor DNA (ctDNA) biomarker in plasma for cancers such as breast, ovarian, and lung cancer [9, 18, 19, 20].

The transcriptional activity of the HOXA9 locus is also controlled by distal enhancer elements. A well-characterized enhancer region, located approximately 50 kilobases downstream of the gene, is bound by the Mixed Lineage Leukemia (MLL) protein complex. MLL, a histone-lysine N-methyltransferase, deposits the H3K4me3 mark at the HOXA9 promoter and protects the CpG clusters within the gene body from DNA methylation, thereby maintaining transcript expression [21]. Disruption of this MLL-mediated protection, either through loss of MLL function or through the action of MLL fusion proteins, is a key step in leukemogenesis [21, 22].

### 1.3 Transcription Factor Binding Sites

The HOXA9 promoter and enhancer regions contain binding sites for a multitude of transcription factors that integrate developmental and stress signals. Key regulators include:

- **MLL/Menin Complex**: Binds to the promoter and proximal enhancer, maintaining an active chromatin state [23].
- **NF-κB**: Exhibits a dual role, capable of both activating and repressing HOXA9 transcription depending on the cellular context and the specific NF-κB subunits involved [1].
- **TGF-β/BMP Signaling**: SMAD proteins, downstream effectors of TGF-β/BMP signaling, can bind to the HOXA9 locus and repress its expression by inhibiting the DNA-binding ability of the HOXA9 protein itself, forming a negative feedback loop [2].
- **Estrogen Receptor (ER)**: In ER-positive breast cancer, estrogen signaling can modulate HOXA9 expression, linking hormonal status to HOX gene dysregulation [3].

### 1.4 Alternative Splicing and Isoforms

While the canonical HOXA9 protein is the most well-studied, alternative splicing generates multiple transcript variants. A notable variant is a TNF-α-regulated isoform expressed in endothelial cells [4]. This variant arises from alternative splicing that alters the N-terminal region of the protein, potentially affecting its interaction with cofactors and its transcriptional activity. The existence of these isoforms adds a layer of functional complexity, allowing HOXA9 to exert context-dependent effects. Furthermore, the presence of "exitrons" (intronic exons) within homeobox genes, including HOXA9, has been proposed as a mechanism for generating additional protein isoforms with potentially altered functions in cancer [5].

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Boundaries

The HOXA9 protein is a classic member of the ANTP class of homeodomain transcription factors. Its primary structure can be divided into two principal functional domains:

1.  **N-Terminal Regulatory Domain (Residues 1-137)**: This region is poorly structured in isolation but is rich in proline, serine, and threonine residues. It contains a conserved hexapeptide motif (also known as the Pbx interaction motif) with the consensus sequence `FDWPKN` (residues 28-33). This motif is essential for the protein's interaction with members of the TALE (three-amino-acid loop extension) class of homeodomain proteins, particularly PBX1 and PBX3 [6, 7]. The N-terminus also contains a transactivation domain that recruits co-activators such as CBP/p300 and is subject to post-translational modifications, including phosphorylation, that modulate its activity [8].
2.  **C-Terminal DNA-Binding Domain (Residues 138-272)**: This region contains the highly conserved 60-amino-acid homeodomain (residues 138-197), which folds into a characteristic helix-turn-helix (HTH) motif. The homeodomain is the primary determinant of DNA-binding specificity. The extreme C-terminus (residues 198-272) is rich in basic amino acids and contributes to nuclear localization and high-affinity DNA binding.

### 2.2 The Homeodomain: A Helix-Turn-Helix Motif

The homeodomain of HOXA9 is the archetypal DNA-binding module. Its three-dimensional structure, solved by NMR spectroscopy (PDB: 1K28), consists of three alpha-helices:

- **Helix I (Residues ~141-153)**: Lies roughly perpendicular to Helix II and is involved in stabilizing the overall fold.
- **Helix II (Residues ~157-166)**: Connected to Helix I by a short loop.
- **Helix III (Residues ~170-190)**: The "recognition helix," which fits directly into the major groove of the DNA double helix. This helix makes the majority of base-specific contacts with the DNA.

The homeodomain binds DNA as a monomer, recognizing a TAAT core motif. The critical base-specific contacts are made by residues in Helix III, particularly isoleucine at position 47 (Ile47) and glutamine at position 50 (Gln50). Gln50 makes a bidentate hydrogen bond with the adenine in the TAAT core, while Ile47 makes hydrophobic contacts with the thymine. The N-terminal arm of the homeodomain (residues 138-140) extends into the minor groove and makes additional contacts that stabilize the protein-DNA interaction.

### 2.3 DNA-Binding Specificity and Cooperativity

While the isolated homeodomain binds to TAAT motifs, its specificity and affinity in vivo are dramatically enhanced by cooperative binding with cofactors. The interaction with PBX proteins is a prime example. The hexapeptide motif in the N-terminus of HOXA9 docks into a hydrophobic pocket on the surface of the PBX homeodomain. This interaction allows the HOXA9-PBX heterodimer to bind to a composite DNA recognition sequence, typically `TGATNNATNN` or `TGATNNATAA` [6]. This cooperative binding increases the DNA-binding affinity by several orders of magnitude and provides a much higher level of target gene specificity than either protein alone. This interaction is critical for HOXA9's role in both normal development and leukemogenesis [7, 9].

### 2.4 Interactive 3D Visualizer

To explore the atomic details of the HOXA9 homeodomain in complex with its DNA target, an interactive 3D visualizer is available.

[Interactive 3D Protein Visualizer: Load HoxA9 (PDB: 1K28)](/tools/protein-structure-viewer?source=direct&pdbId=1K28)

This tool allows users to rotate the structure, highlight specific residues, and visualize the precise interactions between the recognition helix and the DNA major groove.

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Role in Development and Hematopoiesis

HOXA9 is a master regulator of anterior-posterior patterning during embryogenesis. Its expression is spatially restricted along the body axis, with higher expression in the posterior regions of the developing embryo. This expression gradient is crucial for the proper formation of the skeleton, nervous system, and other mesodermal and ectodermal structures [10]. In the developing limb, HOXA9 is involved in the patterning of the stylopod and zeugopod [11].

In the adult, HOXA9 expression is largely restricted to hematopoietic stem and progenitor cells (HSPCs), where it plays a non-redundant role in maintaining the stem cell pool and regulating the balance between self-renewal and differentiation. Targeted disruption of Hoxa9 in mice results in severe defects in myeloid, erythroid, and lymphoid hematopoiesis, leading to a significant reduction in the number of committed progenitors and a marked impairment in the ability of HSPCs to repopulate the bone marrow of irradiated recipients [2]. Mechanistically, HOXA9 functions as a "pioneer" transcription factor, capable of binding to condensed chromatin and initiating the opening of regulatory regions to facilitate the binding of other transcription factors [12]. It directly regulates the expression of genes involved in stem cell self-renewal (e.g., *MEIS1*), proliferation (e.g., *IGF1*), and differentiation blockade (e.g., *GPR56*) [13, 14].

### 3.2 Transcriptional Networks and Downstream Targets

HOXA9 orchestrates complex transcriptional programs by binding to enhancers and promoters of its target genes. A comprehensive noncoding CRISPR screen identified a core set of downstream targets essential for its leukemogenic function [22]. These targets include:

- **Self-Renewal and Stemness**: *MEIS1*, *GPR56*, *JMJD1C* [13, 15].
- **Proliferation and Survival**: *IGF1*, *IGF1R*, *[BRCA1](/knowledge/bioinformatics/genes/cancer-genomics/brca1-gene-mutation-dna-repair)* [3, 14, 16].
- **Differentiation Block**: *CEBPA*, *PU.1* (indirectly repressed).
- **Metabolic Reprogramming**: *HK2*, *LDHA* (via interaction with HIF-1α) [17].

The transcriptional activity of HOXA9 is modulated by a host of cofactors and interacting proteins. It can form complexes with:

- **PBX1/PBX3**: Enhances DNA-binding specificity and transcriptional activity [7].
- **MEIS1**: A critical cofactor that stabilizes the HOXA9-PBX complex and is often co-expressed in aggressive leukemias [18, 19].
- **PRMT5**: The protein arginine methyltransferase 5 binds to HOXA9 and is required for the cytokine-induced expression of E-selectin in endothelial cells, linking HOXA9 to inflammatory responses [20, 21].
- **CRIP2**: A cysteine-rich protein that interacts with HOXA9 to inhibit HIF-1α-mediated glycolysis in cutaneous squamous cell carcinoma [17].

### 3.3 Regulation of HOXA9 Expression

HOXA9 expression is tightly controlled at multiple levels. Epigenetically, the promoter is regulated by DNA methylation and histone modifications. The MLL complex maintains an active chromatin state, while Polycomb Repressive Complex 2 (PRC2) can deposit the repressive H3K27me3 mark [21]. Post-transcriptionally, HOXA9 is a target for several microRNAs (miRNAs), which bind to the 3' untranslated region (UTR) of its mRNA and promote its degradation or translational repression. Key miRNAs regulating HOXA9 include:

- **miR-196b**: Directly targets HOXA9 and regulates aggressiveness in non-small cell lung cancer [22].
- **miR-365**: Induces apoptosis and inhibits invasion in myeloma cells by targeting HOXA9 [23].
- **miR-873**: Inhibits the aggressive phenotype of osteosarcoma by targeting HOXA9 and deactivating the Wnt/β-catenin pathway [1].
- **miR-708**: A novel regulator of the Hoxa9 program in myeloid cells [2].
- **miR-140-3p**: Explored as a regulator of HOXA9 in colorectal cancer [8].

This multi-layered regulation ensures that HOXA9 levels are precisely tuned to the cellular context.

### 3.4 HOXA9 in Endothelial and Mesenchymal Cells

Beyond hematopoiesis, HOXA9 plays a significant role in vascular biology. It is expressed in endothelial cells and is required for the TNF-α-induced expression of E-selectin, a key adhesion molecule involved in leukocyte trafficking [3]. This process is dependent on the interaction of HOXA9 with PRMT5 and NF-κB [20, 21]. HOXA9 also inhibits NF-κB-dependent activation of the endothelium, suggesting a complex, context-dependent role in inflammation [4]. In vascular smooth muscle cells, HOXA9 regulates phenotypic switching and proliferation by modulating methyl-CpG binding protein 2 (MECP2) [5]. In mesenchymal cells, HOXA9 expression is associated with keloid formation, a fibroproliferative disorder, and its expression is higher in anterior versus posterior body regions, correlating with the anatomical distribution of keloids [6].

```mermaid
sequenceDiagram
    participant Ligand as "TNF-α"
    participant Receptor as "TNFR1"
    participant Cytoplasm as "Cytoplasm"
    participant NFkB as "NF-κB (p50/p65)"
    participant Nucleus as "Nucleus"
    participant HOXA9 as "HOXA9"
    participant PRMT5 as "PRMT5"
    participant Gene as "E-selectin Gene"
    Ligand->>Receptor: Binds
    Receptor->>Cytoplasm: Activates IKK complex
    Cytoplasm->>NFkB: Phosphorylates IκBα (Degradation)
    NFkB->>Nucleus: Translocates
    NFkB->>Gene: Binds to κB site
    Nucleus->>HOXA9: Recruits HOXA9 & PRMT5
    HOXA9->>Gene: Binds to HOX site
    PRMT5->>Gene: Methylates Histones (Activation)
    Gene->>Gene: Increased Transcription of E-selectin
```

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Chromosomal Translocations and Fusion Proteins

The most well-characterized pathogenic alteration involving HOXA9 is the t(7;11)(p15;p15) translocation, which creates the NUP98-HOXA9 fusion gene [13]. This fusion is found in a small subset of AML and MDS patients and is associated with a poor prognosis [3, 14]. The NUP98-HOXA9 fusion protein retains the N-terminal FG-repeat domain of NUP98, which has intrinsic transcriptional activation properties, fused to the C-terminal DNA-binding homeodomain of HOXA9. This chimeric protein acts as a potent aberrant transcription factor, driving the expression of HOXA9 target genes and blocking hematopoietic differentiation [7, 15]. Variant complex translocations involving NUP98-HOXA9 have also been reported [8]. Other NUP98 homeobox fusions, such as NUP98-HOXC13 and NUP98-PMX1, share a similar mechanism of action, underscoring the importance of this class of oncogenes in leukemogenesis [9, 10, 11].

### 4.2 Aberrant Expression and Epigenetic Dysregulation

In the majority of AML cases, particularly those with MLL rearrangements (MLL-r) or NPM1 mutations, HOXA9 is not mutated but is aberrantly overexpressed [7, 12, 13, 14]. This overexpression is a hallmark of the disease and is a strong predictor of poor prognosis [9, 15]. The overexpression is driven by the fusion oncoproteins (e.g., MLL-AF9), which aberrantly recruit histone-modifying enzymes like DOT1L and LSD1 to the HOXA9 locus, leading to a sustained active chromatin state [16]. Conversely, in many solid tumors, HOXA9 acts as a tumor suppressor, and its expression is silenced through promoter hypermethylation. This is observed in hepatocellular carcinoma [5], oral squamous cell carcinoma [16], and non-small cell lung cancer [17]. The methylation status of HOXA9 is being actively investigated as a prognostic and predictive biomarker [7, 17, 18].

### 4.3 Point Mutations and Polymorphisms

Unlike classical oncogenes such as RAS or TP53, recurrent point mutations in the HOXA9 coding sequence are rare. The pathogenic mechanisms are predominantly driven by copy number alterations, epigenetic silencing, or transcriptional dysregulation. However, single nucleotide polymorphisms (SNPs) in the HOXA9 regulatory regions may contribute to inter-individual variability in expression levels and disease susceptibility. The functional significance of most of these variants remains to be fully characterized. The primary clinical differential for HOXA9 dysregulation is therefore based on expression levels and methylation status rather than coding sequence mutations.

### 4.4 HOXA9 in Solid Tumors: A Context-Dependent Role

The role of HOXA9 in solid tumors is highly context-dependent, acting as either an oncogene or a tumor suppressor.

- **Oncogenic Role**: In ovarian cancer, high HOXA9 expression is linked to a serous papillary histotype and is associated with poor prognosis [4]. It promotes tumor growth by inducing peritoneal macrophages to acquire an M2 tumor-promoting phenotype [19]. In colorectal cancer, upregulated HOXA9 expression is associated with lymph node metastasis [10]. In glioblastoma, a HOXA9-mediated transcriptomic signature promotes tumor initiation, aggressiveness, and resistance to temozolomide [11]. In non-small cell lung cancer, HOXA9 can drive the expression of oncogenic fusion genes like EPHB4-MET [6].
- **Tumor Suppressive Role**: In cutaneous squamous cell carcinoma, HOXA9 is significantly downregulated and acts to inhibit glycolysis and tumor development by interacting with CRIP2 to repress HIF-1α [17]. In breast cancer, HOXA9 regulates BRCA1 expression, and its loss can contribute to a more aggressive, basal-like phenotype [3]. The re-expression of HOXA9 in three-dimensional organotypic culture of Claudin-low breast cancer cells suggests that the tumor microenvironment can influence its epigenetic silencing [20].

## 5. Host-Pathogen & Viral Interactions

### 5.1 Human Cytomegalovirus (HCMV)

Human cytomegalovirus (HCMV) infection has been shown to affect the expression of HOXA9 in hematopoietic progenitor cells. Specifically, HCMV infection can alter the expression of HOXA9 and HOXA10 during granulocyte differentiation, potentially contributing to the myelosuppression and hematopoietic dysfunction observed in infected individuals [21, 22]. The exact mechanism by which HCMV modulates HOXA9 expression is not fully understood but may involve viral proteins interfering with host transcription factors or epigenetic machinery.

### 5.2 Human Papillomavirus (HPV)

In cervical carcinoma, the expression of homeobox genes, including HOXA9, is altered. Studies have shown that HPV infection is associated with changes in HOX gene expression patterns, which may contribute to the dysregulation of epithelial differentiation and the development of cervical cancer [23]. The viral oncoproteins E6 and E7 are known to interact with and degrade tumor suppressor proteins like p53 and Rb, and it is plausible that they also indirectly influence the expression of developmental regulators like HOXA9.

### 5.3 Other Viral Interactions

The NUP98-HOXA9 fusion protein itself can be considered a "pathogenic" entity, but it is not of viral origin. However, the transcriptional program it drives can create a cellular environment that is more permissive to viral infection or reactivation. For example, HOXA9's role in regulating E-selectin expression in endothelial cells could influence the trafficking of virus-infected leukocytes [3]. The interaction between HOXA9 and the host cell's epigenetic machinery also makes it a potential target for viral manipulation, as many viruses encode proteins that interact with histone-modifying enzymes.

## 6. [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), Drug Targets & Small-Molecule Inhibitors

### 6.1 Targeting the Menin-MLL Interaction

Since HOXA9 overexpression in MLL-r AML is driven by the Menin-MLL interaction, disrupting this complex is a highly promising therapeutic strategy. Small-molecule inhibitors of the Menin-MLL interaction, such as **DSP-5336 (Enzomenib)**, have shown potent preclinical activity against MLL-r and mutant-NPM1 AML models by downregulating HOXA9 and MEIS1 expression [23]. These inhibitors are currently in clinical trials and represent a paradigm-shifting approach to targeting HOXA9-driven leukemia.

### 6.2 Epigenetic Modulators

Given that HOXA9 expression is controlled by epigenetic marks, inhibitors of histone-modifying enzymes are being explored as a means to downregulate its expression in leukemia.

- **DOT1L Inhibitors**: DOT1L is a histone methyltransferase that is recruited by MLL fusion proteins to maintain HOXA9 expression. Inhibitors of DOT1L, such as pinometostat, have been shown to reduce HOXA9 expression and inhibit leukemic cell growth [16].
- **LSD1 Inhibitors**: LSD1 (KDM1A) is a histone demethylase that also plays a role in maintaining HOXA9 expression in MLL-r leukemia. LSD1 inhibitors have shown efficacy in preclinical models [16].
- **HDAC Inhibitors**: Histone deacetylase (HDAC) inhibitors can have dual effects. While they can reactivate silenced tumor suppressors, they can also downregulate HOXA9 expression in certain contexts, as HDAC activity is essential for HOXA9 expression in endothelial progenitor cells [1]. The effects are highly context-dependent [16].

### 6.3 Direct HOXA9 Inhibitors

The homeodomain of HOXA9 is a challenging but attractive drug target. Small molecules that bind to the homeodomain and block its interaction with DNA have been identified. One such compound, **DB818**, has been shown to inhibit the growth of AML cells in vitro by interfering with HOXA9-dependent transcription [2]. Another study identified small molecules that overcome HoxA9-mediated differentiation arrest in AML, providing a proof-of-concept for targeting HOXA9 function directly [3]. Natural compounds like **17β-neriifolin** have also been shown to suppress cell proliferation by inhibiting HOXA9-dependent transcription in AML cells [4].

### 6.4 RNA Interference and Gene Therapy

RNA interference (RNAi) approaches using short hairpin RNAs (shRNAs) or small interfering RNAs (siRNAs) targeting HOXA9 have been extensively studied in preclinical models. Lentivirus-mediated shRNA targeting HOXA9 has been shown to inhibit proliferation, induce apoptosis, and enhance drug sensitivity in human AML cell lines [5, 6, 7]. These approaches validate HOXA9 as a therapeutic target but face significant challenges in clinical translation, including efficient delivery to leukemic stem cells.

### 6.5 MicroRNA-Based Therapeutics

Since HOXA9 is negatively regulated by several miRNAs, restoring the expression of these miRNAs could be a therapeutic strategy. For example, miR-365, miR-873, and miR-708 have all been shown to inhibit HOXA9 expression and suppress tumor growth in various models [1, 2, 23]. miRNA mimics or viral vectors expressing these miRNAs are being explored as potential therapeutic agents.

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Identifier** | **Description** |
| :--- | :--- | :--- |
| **NCBI Gene** | 3205 | Primary gene information, genomic context, and reference sequence. |
| **Ensembl** | ENSG00000165992 | Comprehensive genome annotation, transcripts, and variation data. |
| **UniProtKB** | P31269 | Protein sequence, function, domain architecture, and post-translational modifications. |
| **RCSB PDB** | 1K28 | Experimentally determined 3D structure of the HOXA9 homeodomain. |
| **HGNC** | 5109 | Official gene symbol and nomenclature. |
| **OMIM** | 142955 | Mendelian inheritance and disease associations. |
| **ClinVar** | 3205 | Human variations and their relationship to disease. |
| **STRING** | 3205 | Protein-protein interaction networks. |
| **BioGRID** | 112158 | Physical and genetic interactions. |
| **Gene Ontology (GO)** | GO:0003700, GO:0005634, GO:0000978 | Molecular function (DNA-binding transcription factor), cellular component (nucleus), and biological process (anterior/posterior pattern specification). |
| **Cancer Gene Census (COSMIC)** | HOXA9 | Curated information on cancer-related mutations and fusions. |

## Related Clinical & Scientific Guides

* [GFP (Green Fluorescent Protein): Beta-Barrel Chromophore Physics, Fluorophore Engineering, and Live-Cell Imaging](/knowledge/bioinformatics/genes/model-organisms/gfp-gene-structure-function-pathway)
* [cdc28 (CDK1): Master Cyclin-Dependent Kinase of Cell Cycle Transitions and Cell Division Control](/knowledge/bioinformatics/genes/model-organisms/cdc28-gene-structure-function-pathway)
* [Sonic Hedgehog (Shh): Morphogen Gradient Signaling, Autoproteolytic Cleavage, and Holoprosencephaly](/knowledge/bioinformatics/genes/model-organisms/shh-gene-structure-function-pathway)

## References

[1] He, L., Feng, X., Hu, C., Liu, S., Sheng, H., Cai, B., & Ma, Y. (2024). HOXA9 gene inhibits proliferation and differentiation and promotes apoptosis of bovine preadipocytes. *BMC Genomics*. https://www.semanticscholar.org/paper/ef3fb53d2eee43a72d485ae0fb81df8d7fb215a3

[2] Lawrence, H., Helgason, C., Sauvageau, G., Fong, S., Izon, D., Humphries, R., & Largman, C. (1997). Mice bearing a targeted interruption of the homeobox gene HOXA9 have defects in myeloid, erythroid, and lymphoid hematopoiesis. *Blood*. https://www.semanticscholar.org/paper/e62026c77bdd85bccba4664972108465bdbbc522

[3] TUMORIGENESIS AND NEOPLASTIC PROGRESSION Expression of the Homeobox Gene HOXA9 in Ovarian Cancer Induces Peritoneal Macrophages to Acquire an M2 Tumor-Promoting Phenotype. https://www.semanticscholar.org/paper/686e7eebf0cd7477029241bef5b956f74e6d936a

[4] Kwong, Y., & Pang, A. (1999). Low frequency of rearrangements of the homeobox gene HOXA9/t(7;11) in adult acute myeloid leukemia. *Genes, Chromosomes and Cancer*. https://www.semanticscholar.org/paper/c9d509d5d1003c1628fb6fc59148e534f7ca0136

[5] Trivedi, C., Patel, R. C., & Patel, C. V. (2007). Homeobox gene HOXA9 inhibits nuclear factor-kappa B dependent activation of endothelium. *Atherosclerosis*. https://www.semanticscholar.org/paper/21299c385f98953989e9a35ae9fc01dd5758063b

[6] Li, X., Zhang, H., & Huo, Y. (2022). High HOXA9 gene expression predicts response to chemotherapy and prognosis of high-grade serous ovarian cancer patients. *Journal of International Medical Research*. https://www.semanticscholar.org/paper/e6631d9eb07810b3804aa3572c7dc65d4b792e93

[7] Jia, X., Zhu, L., Li, J., & Wang, C. (2013). Expression of homeobox gene HOXA9 in childhood acute leukemia, and its clinical significance. *Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics*. https://www.semanticscholar.org/paper/1ab1a703269df7f62ae0122a1a432be7cf76c6e8

[8] Daria, D., Muranyi, A., Ihme, S., Döhner, K., Döhner, H., Feuring-Buske, M., & Buske, C. (2014). The Adhesion Molecule "G-Protein Coupled Receptor 56" (Gpr56) Cooperates with the Homeobox Gene Hoxa9 to Induce Acute Myeloid Leukemia in Mice. https://www.semanticscholar.org/paper/0f7d4e2aa4340bfb58c37e6348f6a76f75867b70

[9] Wen-jun, L. (2010). Expression of HOXA9 homeobox gene in Granulocyte differentiation infected with HCMV. https://www.semanticscholar.org/paper/53355e888ffe93ccee9bc27f340cadc25a76c795

[10] Yanmin, H., Faming, Z., & Lixing, Y. (2010). Construction and identification of recombinant retrovirus vector containing human homeobox gene HOXA9. https://www.semanticscholar.org/paper/5e33ad630fef28db98c659b01da452a642d595fc

[11] Tallima, Z., Ibraheem, D., Wilson, M., & Elfishawi, S. (2025). Variability in expression of homeobox genes (HOXA9) and (HOXA7) in acute myeloid leukemia patients. *Current Research in Translational Medicine*. https://www.semanticscholar.org/paper/de0f1c1606a38e96eae55cc6b4e8878dba6e89db

[12] Ko, S. (2013). THE ROLE AND MECHANISM OF THE HOMEOBOX GENE HOXA9 IN THE GROWTH OF EPITHELIAL OVARIAN CANCER. https://www.semanticscholar.org/paper/9daaaa1d027d2f6cf307c578e9414adc49fd62ec

[13] Kuo, C., Lin, C., Shih, Y., Hsieh, C., Lin, P., Guan, S., Hsieh, M., Lai, H., Chen, C., & Lin, Y. (2014). Frequent methylation of HOXA9 gene in tumor tissues and plasma samples from human hepatocellular carcinomas. *Clinical Chemistry and Laboratory Medicine*. https://www.semanticscholar.org/paper/b6000936637f29a172aad4f2fd1ada0ac4eba4d9

[14] Xia, W., Zhu, W., Feng, D., Xu, Y., Liu, T., & Xu, L. (2026). Fusion Gene EPHB4-MET Driven by HOXA9 and Exerted Oncogenic Activity in Non-Small Cell Lung Cancer. *Critical Reviews in Immunology*. https://www.semanticscholar.org/paper/15e7bfac19d1ffe7d72d2587ac2841271a6d2060

[15] Huret, J. (2010). HOXA9 (homeobox A9). https://www.semanticscholar.org/paper/a7837f522ccf8c043e7d20c2fc3e86db5d74de03

[16] Li, D., Li, Z., Sang, W., Cheng, H., Pan, X., & Xu, K. (2013). HOXA9 Gene Expression in Acute Myeloid Leukemia. *Cell Biochemistry and Biophysics*. https://www.semanticscholar.org/paper/143b591e1cb1d35374049919119f3e0324286c97

[17] Xie, F., Zhang, T., Zhang, X., Xu, Z., Qiao, L., Wang, Y., Zhao, Y., Qian, J., & Zhou, J. (2025). Identification of HOXA9 methylation as an epigenetic biomarker predicting prognosis and guiding treatment choice in acute myeloid leukemia. *BMC Cancer*. https://www.semanticscholar.org/paper/e3871f7d01e14055294cf2e4bed721b5625d759b

[18] Hahn, J., McFarland, K., Combs, K., Anness, M., & Supp, D. (2021). Analysis of HOX gene expression and the effects of HOXA9 overexpression in fibroblasts derived from keloid lesions and normal skin. *Wound Repair and Regeneration*. https://www.semanticscholar.org/paper/ccad5dc7df62ffdf674605c45e66b909db68a472

[19] Gao, Y., Miao, Y., Zhang, W., Ru, X., & Hou, L. (2021). MicroRNA-365 induces apoptosis and inhibits invasion of human myeloma cells by targeting homeobox A9 (HOXA9). *Environmental Toxicology and Pharmacology*. https://www.semanticscholar.org/paper/5a69c63bac0a9b54bdaceef774f51b466add153a

[20] Erfurth, F., Popovic, R., Grembecka, J., Cierpicki, T., Theisler, C., Xia, Z., Stuart, T., Diaz, M., Bushweller, J., & Zeleznik-Le, N. (2008). MLL protects CpG clusters from methylation within the Hoxa9 gene, maintaining transcript expression. *Proceedings of the National Academy of Sciences of the United States of America*. https://www.semanticscholar.org/paper/0c5dbc721b0fd655a7b02411e2283d6ba0e3c06e

[21] Zheng, D., Ning, J., Xia, Y., Ruan, Y., & Cheng, F. (2022). Comprehensive analysis of a homeobox family gene signature in clear cell renal cell carcinoma with regard to prognosis and immune significance. *Frontiers in Oncology*. https://www.semanticscholar.org/paper/db06244e1afb0bdcd1ce966885fb8e6c230f3b7a

[22] Rodrigues, M. F. D., Xavier, F., Esteves, C. D., Nascimento, R. B., Nobile, J. S., Severino, P., de Cicco, R., Toporcov, T., Tajara, E., & Nunes, F. (2021). Homeobox gene amplification and methylation in oral squamous cell carcinoma. *Archives of Oral Biology*. https://www.semanticscholar.org/paper/554df93a85aaa261680aa6f8f0de89e27951ffdf

[23] Kandel, S. H., Ahmedy, I., Tayel, S., & Mohamed, A. (2021). Role